Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

COTA Appoints C.K. Wang, M.D. as New Chief Medical Officer

Dr. Wang’s Commitment to COTA’s Mission and Extensive Oncology Background Supports the Company’s Next Stage of Growth and Ongoing Partnerships

COTA, Inc., a healthcare technology company that uses real-world data (RWD) to bring clarity to cancer care, announced its board of directors has appointed C.K. Wang, M.D. as the company’s chief medical officer (CMO). Since joining COTA in 2018, Dr. Wang has demonstrated his dedication to advancing COTA’s mission of improving cancer care and treatment through his leadership of clinical data abstraction operations. In his new role, Dr. Wang will be leading the medical team to meet the interest and demand for real-world data in cancer care.

“Since joining COTA, I’ve been able to collaborate with provider and life science partners as we move closer to our shared vision that everyone touched by cancer receives a clear path to care,” said Dr. Wang. “We’re on the cusp of truly changing how real-world data is applied in cancer care and drug discovery, and I look forward to continuing to drive this industry transformation in my expanded role.”

Recommended AI News: Securing E-Commerce By Investing In Cybersecurity

Related Posts
1 of 36,557

“As COTA enters its next phase of growth, we are proud that our executive leadership team is fully aligned and embodies a steadfast commitment to our mission of bringing clarity to cancer care,” said Mike Doyle, President and CEO of COTA. “Dr. Wang’s impact on our organization to date has been truly remarkable. His perspective, developed from over a decade managing cancer practices and establishing new cancer programs, will be a great asset to COTA as we develop new oncology solutions to serve our partners across the industry. We look forward to applying his unique skill set across a broader set of initiatives as we continue to improve cancer care for patients.”

Recommended AI News: We Live And Breathe Data And Technology – Sans Ego: Silverbullet CEO Ian James

Prior to working with COTA, Dr. Wang served as the Acting Deputy Chief Health Officer for Oncology/Genomics and the Global Oncology Leader at IBM Watson Health.  Earlier in his career as a medical oncologist, Dr. Wang worked in private practice in the Dallas/Fort Worth area where he held multiple management and leadership positions including managing partner   with Dallas Oncology Consultants, P.A., Director of Oncology with Medical Clinics of North Texas, P.A. and Cancer Program Chairman with the USMD Hospital in Arlington. He received his undergraduate training at Washington University in St. Louis and his M.D. from the University of Texas Health Science Center at San Antonio before completing his residency at University Hospitals in Cleveland, OH and his hematology/ oncology fellowship at the University of Texas Southwestern Medical Center.

Recommended AI News: SaaS Versus Cloud: How AIOps Is Impacting Both

Comments are closed, but trackbacks and pingbacks are open.